Literature DB >> 3946412

Common variable hypogammaglobulinemia in pregnancy: treatment with high-dose immunoglobulin infusions.

D L Madsen, V A Catanzarite, F Varela-Gittings.   

Abstract

Pregnancy outcomes when the mother has common variable hypogammaglobulinemia are poor unless immunoglobulin levels are returned to normal or near-normal range. Intravenous immunoglobulin infusions are the favored mode of therapy. Here, we report the fifth patient so treated. Weekly doses of 200 mg/kg during the third trimester were required. A healthy term baby was delivered and the postpartum course was uncomplicated.

Entities:  

Mesh:

Year:  1986        PMID: 3946412     DOI: 10.1002/ajh.2830210313

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  5 in total

1.  IgG replacement therapy for primary hypogammaglobulinaemia during pregnancy: report of 9 pregnancies in 4 patients.

Authors:  P E Williams; C L Leen; A D Heppleston; P L Yap
Journal:  Blut       Date:  1990-03

2.  Intravenous immunoglobulin replacement therapy for common variable immunodeficiency during pregnancy.

Authors:  H Osada; Y Morikawa; T Nishiwaki; S Sekiya
Journal:  Arch Gynecol Obstet       Date:  1996       Impact factor: 2.344

3.  Rapid subcutaneous IgG replacement therapy at home for pregnant immunodeficient women.

Authors:  A Gardulf; E Andersson; M Lindqvist; S Hansen; R Gustafson
Journal:  J Clin Immunol       Date:  2001-03       Impact factor: 8.317

4.  Pregnancy Outcome in Patients with Common Variable Immunodeficiency.

Authors:  Pavlina Kralickova; Barbora Kurecova; Ctirad Andrys; Irena Krcmova; Dalibor Jilek; Marcela Vlkova; Jiri Litzman
Journal:  J Clin Immunol       Date:  2015-08-18       Impact factor: 8.317

5.  Fertility, pregnancies and outcomes reported by females with common variable immune deficiency and hypogammaglobulinemia: results from an internet-based survey.

Authors:  Adi V Gundlapalli; Christopher Scalchunes; Marcia Boyle; Harry R Hill
Journal:  J Clin Immunol       Date:  2015-01-09       Impact factor: 8.317

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.